Clinical consequence of the cell-mediated antitumor immunity polymorphism in patients with B-cell lymphoma treated with rituximab

Czech version

Authors: V. Procházka; T. Papajík; Z. Kubová; M. Novák; Z. Pikalová; Š. Rožmanová; M. Jarošová; K. Indrák
Authors‘ workplace: Hemato-onkologická klinika Fakultní nemocnice Olomouc
Published in: Transfuze Hematol. dnes,15, 2009, No. 4, p. 224-228.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

The introduction of rituximab therapy into the treatment of B-cell non-Hodgkin’s lymphoma has brought unprecedented improvements in treatment outcomes across the whole population of patients. Although resistance to rituximab is rare, some patients show a poorer treatment response. Detailed study of the mechanisms of rituximab activity showed that the main effector mechanisms leading to the destruction of lymphoma cells are those related to a patient’s antitumor immunity: complement-dependent cellular cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Study of rituximab interaction with a patient’s T-lymphocytes and NK cells suggests considerable interindividual variability in the severity of the cytotoxic response. The first laboratory and clinical data show that variable quantity and quality of ADCC may be associated with the effectiveness of immunotherapy in a particular patient.

Key words:
rituximab, immunotherapy, B-cell lymphoma

Sources

1. Ghielmini M, Schmitz SF, Burki K, et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11 Suppl 1: 123-6.

2. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105(4): 1417-23.

3. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 Dec 1; 106(12): 3725-32.

4. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006 Nov 15; 108 (10): 3295-301.

5. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007 May 2; 99 (9): 706-14.

6. Forstpointner R, Unterhalt M, Dreyling M, et al. German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006 Dec 15; 108 (13): 4003-8.

7. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 Jul 1; 24 (19): 3121-7.

8. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d‘Etude des Lymphomes de l‘Adulte. J Clin Oncol 2005 Jun 20; 23 (18): 4117-26.

9. Pfreundschuh M, Trumper L, Osterborg A, et al. MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 May; 7 (5): 379-91.

10. Trneny M, Rieger M, Osterborg A, et al. The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study. Blood Nov 2008; 112: (Abstract#839).

11. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007 Apr; 62 (1): 43-52.

12. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004 Nov 1; 104 (9): 2635-42.

13. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006 Feb; 91 (2): 176-83.

14. Fijen CA, Bredius RG Kuijper EJ, et al. The role of Fχc receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol 2000; 120: 338-345.

15. Dijstelbloem HM, Scheepers RH, Oost WW, et al. Fχc receptor polymorphisms in Wegeneręs granulomatosis: risk factors for disease relapse. Arthritis Rheum 1999; 42: 1823-1827.

16. DallęOzzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: infuence of FCGR3A polymorphism on the concentration-effect relationship. Cancer research 2004; 64: 4664-4669.

17. Hatjiharissi E, Hansen M, Santos DD, et al. Genetic linkage of FγcRIIa and FγcRIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007; 7: 286-290.

18. Hatjiharissi E, Santos D, Xu L, et al. Individuals expressing FcgRIIIA-158 V/V and V/F show increased NK cell surface expression of FcgRIIIA (CD16), rituximab binding, and demonstrate higher levels of ADCC activity in response to rituximab. Blood 2005; 106: 229a (Abstract #776).

20. Bowles JA, Weiner GJ. CD16 polymorphisms nad NK activation induced by monoclonal antibody-coated cells. Journal of Immunological Methods 2005; 304: 88-99.

21. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FγcRIIIa gene. Blood 2002; 99: 754-757.

22. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal Clin Oncol 2003; 21: 3940-3947.

23. Prochazka V, Rozmanova S, Papajik T, et al. Risk-adapted immunochemotherapy overcomes the negative prognostic impact FCGRIIIA of the receptor genotype in patients with follicular lymphoma. Haematologica 2007; 92[suppl.2]: 107.

24. Penack O, Gentilini C, Fischer L, et al. CD56dimC D16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 2005 May; 19 (5): 835-40

25. Fischer L, Penack O, Gentilini Ch, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Experimental Hematology 2006; 34: 753–759.

26. Prochazka V, Novak M, Pikalova Z, et al. Rituximab enhances cellular mediated cytotoxicity in patients with B-cell lymphoma: in vivo study of NK/T-cells activity. Haematologica 2007; 92[suppl.2]: 111.

27. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients‘ survival benefit from rituximab. Eur J Haematol 2008: 81 (6): 448-53.

28. Porrata LF, Ristow K, Habermann TM, et al. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2008; 84 (2): 93-97.

29. Procházka V, Papajík T, Trněný M, et al. Analýza přežití nemocných s difúzním velkobuněčným B-lymfomem starších 60 let z registru Kooperativní lymfomové skupiny. Trans Hemat dnes 2009; 15: 10-11.

30. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008 Nov 5; 112 (10): 4170-7.

31. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res 2008 Oct 15; 68 (20): 8384-92.

Labels

Haematology Internal medicine Clinical oncology

Assessment of minimal residual disease in B-cell chronic lymphocytic leukemia: options and advancement of techniques based on PCR and RT-PCR

Analysis of myelodysplastic syndrome patients with deletion of long arm of chromosome 5 followed up by the Czech MDS Working Group. Significance for the diagnostic and prognostic assessment

Use of secondary prophylaxis with recombinant activated factor VII in haemophilia A with inhibitor: our experience and the review of the literature

Congenital polycythemias

The role of FLT3 mutations in the pathogenesis of acute myeloid leukemia

Allogeneic stem cell transplantations in multiple myeloma patients – single center experience

Article was published in

Transfusion and Haematology Today

2009 Issue 4